TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

RECRUITINGOBSERVATIONAL

Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis

Acquisition and Persistence of Rifampicin Resistance in Staphylococcus Aureus During and After Treatment for Latent Tuberculosis

About This Trial

Two commonly used treatments for latent tuberculosis infection are either 4 months rifampicin or 6-9 months isoniazid. The invistigators will study the risk of acquisition of rifampicin resistance in commensal Staphylococcus aureus in persons treated with rifampicin versus in persons treated with isoniazide. Through repeated swab cultures before, during, and after treatment the investigators will also investigate potential accumulation of mutations associated with rifampicin resistance over time. Finally, household contacts to persons with rifampicin-resistant S. aureus will be examined to investigate whether onward transmission of rifampicin-resistant S. aureus occurs within households.

Who May Be Eligible (Plain English)

Who May Qualify: - diagnosed with latent tuberculosis - prescribed either 4 months rifampicin or 6-9 months isoniazide - willing to sign a consent form Who Should NOT Join This Trial: - none Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * diagnosed with latent tuberculosis * prescribed either 4 months rifampicin or 6-9 months isoniazide * informed consent Exclusion Criteria: * none

Treatments Being Tested

OTHER

No intervention is part of the study protocol

No intervention is part of the study protocol. The choice of treatment for latent tuberculosis is is made by the treating physician.

Locations (1)

Skåne University Hospital

Malmo, Sweden